A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.
The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]
The professor of neurology and biostatistician at University of Melbourne and Royal Melbourne Hospital spoke on stem cell transplantation in patients with MS and its effectiveness in comparison with other traditional approaches. [WATCH TIME: 2 minutes]
The professor of clinical neurology at University of Miami and MT2020+ chair, and president of Medtronic's Neurovascular Business discussed the effort to improve global accessibility of mechanical thrombectomy.
The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.
Magnetoencephalography provides an opportunity for physicians to capture a more dynamic view of brain function over time and space that may offer an advantage to clinical care.
The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.
Episode 20 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Cormac O'Donovan, MD, of Wake Forest Baptist. [WATCH TIME: 4 minutes]
The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Surgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.
The scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]
Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
The chief medical officer of Cognetivity Neurosciences outlined the benefits a new integrated assessment has for clinicians and patients with dementias and multiple sclerosis. [WATCH TIME: 4 minutes]
Achieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]
Alise Carlson, MD, resident of Cleveland Clinic, details the factors and long-term effects misdiagnosing a patient with multiple sclerosis can have on their quality of life.
Bradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.
David G. Standaert, MD, PhD; Wolfgang Muhlhofer, MD; and Latisha Sharma, MD, share their experience in applying simulation-based learning in Neurology and will discuss the current state and future potential of this approach. [WATCH TIME: 1 hour, 25 minutes]
Drs Jeffrey Dunn and Regina Berkovich review available tools and resources for the care of patients with multiple sclerosis, focusing on specific symptoms.
Advancements in gene therapy approaches have opened the door for a glimpse into the future of care for a number of diseases.
A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how advocacy organizations can help guide patients with epilepsy and their caregivers with a seizure action plan.
Drs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
The assistant professor of biostatistics at Washington University in St. Louis discussed what role the COViMS registry can play for the MS community at this stage in the pandemic.
The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]